LOR-2040: Phase II data

In an open-label, U.S. Phase II trial in 25 patients, LOR-2040 plus high-dose cytarabine (HiDAC) led to a 28% rate of complete remission (CR) or CR with incomplete blood count recovery (CRi). Addition...